Whitehawk Therapeutics (WHWK) Enterprise Value (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Enterprise Value data on file, last reported at -$211.3 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 8.57% year-over-year to -$211.3 million in Q1 2026; TTM through Mar 2026 was -$211.3 million, a 8.57% increase from a year earlier, with the FY2025 full-year figure at -$145.7 million, down 208.44% from the prior year.
• Enterprise Value for Q1 2026 stood at -$211.3 million, down from -$145.7 million in the prior quarter.
• Over the last five years, Enterprise Value for WHWK reached as high as -$47.2 million in Q4 2024 and fell as low as -$231.1 million in Q1 2025.
• Historically, Enterprise Value has averaged -$136.6 million across 5 years, with a median of -$134.9 million in 2023.
• Across the five-year window, Enterprise Value plunged 232.87% in 2022 and surged 56.6% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$172.6 million in 2022, then jumped by 36.92% to -$108.8 million in 2023, then jumped by 56.6% to -$47.2 million in 2024, then tumbled by 208.44% to -$145.7 million in 2025, then sank by 44.99% to -$211.3 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$211.3 million in Q1 2026, -$145.7 million in Q4 2025, and -$162.6 million in Q3 2025.